Biosimilars for Remicade: An IBD Patient Guide

If your insurer or infusion center wants to replace Remicade with another infliximab product, the new name can make a familiar treatment feel unfamiliar. The Food and Drug Administration defines a biosimilar as a biologic that is highly similar to its reference product, with no clinically meaningful differences in safety or effectiveness. FDA also says a biosimilar has the same strength, dosage, treatment benefits, and potential side effects as its reference product. Those standards apply to the biosimilars for Remicade listed in the FDA Purple Book. Your practical questions will usually concern the exact product, the infusion provider, insurance authorization, and your share of the cost.

Remicade biosimilar names and manufacturers

As of August 2026, the FDA Purple Book identifies four Remicade biosimilars: Inflectra (infliximab-dyyb), Renflexis (infliximab-abda), Ixifi (infliximab-qbtx), and Avsola (infliximab-axxq). The database lists Celltrion as the applicant for Inflectra, Samsung Bioepis for Renflexis, Pfizer Ireland Pharmaceuticals for Ixifi, and Amgen for Avsola. It also marks Ixifi as discontinued, illustrating why FDA approval and current availability are separate questions.

The currently listed products use 100 mg single-dose vials for intravenous administration. The current Avsola prescribing information, for example, includes adult and pediatric Crohn's disease and ulcerative colitis. An infusion center may stock only one infliximab product, so ask which exact brand and four-letter suffix will appear on the medication record and claim.

What switching evidence shows

FDA approval means the biosimilar has no clinically meaningful difference from Remicade for the approved conditions of use. Biosimilars differ from generic copies because biologics are produced in living systems and naturally have small variations. The FDA reviews those differences and requires the same treatment risks and benefits.

Evidence in inflammatory bowel disease is strongest for infliximab because it has been used through multiple waves of switching. A 2024 systematic review of 85 publications found that clinical effectiveness after switching was consistent with originator infliximab, with no unexpected serious adverse events. The authors noted that evidence about repeated switches was more limited than evidence about a single switch. The product label still matters after any switch because infliximab products carry important warnings, including serious infections and malignancy, and can cause infusion reactions.

Insurance implications for infliximab biosimilars

Infliximab is administered by a clinician, so coverage commonly involves the medical benefit, the infusion facility, and a product-specific billing code. Medicare Part B, for example, covers biological products furnished incident to physician services, and the Centers for Medicare and Medicaid Services describes a temporary payment increase for qualifying biosimilars. Commercial plans set their own policies, preferred products, prior authorization rules, and infusion locations.

Out-of-pocket spending can remain high even when a biosimilar has a lower price. FDA leaves insurance reimbursement to payers and advises patients to ask their insurer what the plan covers. Before the next infusion, confirm the approved product, authorization dates, facility network status, deductible, coinsurance, and any assistance program. If the plan is changing products, ask whether the existing authorization transfers or whether the gastroenterology office must submit a new request. The Crohn's & Colitis Foundation's biosimilar guidance also recommends asking when the change takes effect, whether the infusion center supplies the new product, and what it will cost.

Ask the insurer to state the preferred infliximab product in writing and share that notice with the prescribing office. The office can compare the payer's choice with the infusion center's inventory and submit supporting records before the next appointment. If the requested product is unavailable or clinically inappropriate, ask the plan which exception or appeal process applies. Record the names and reference numbers from every call so the office, facility, and insurer can resolve conflicting instructions efficiently.

What to document before and after a switch

Write down the full product name and suffix for every infusion. Save the infusion date, dose, facility, authorization number, explanation of benefits, and any delays. A clinical baseline can include stool frequency, bleeding, urgency, abdominal pain, energy, recent C-reactive protein or fecal calprotectin results, and any infliximab drug-level or antibody testing ordered by your clinician. These records help your care team evaluate a reported change without assuming that timing alone proves a medication problem.

Contact the gastroenterology team promptly about worsening IBD symptoms, a delayed infusion, or a new reaction. The Avsola label lists infections and infusion-related reactions among common adverse reactions, and the same label directs clinicians to assess patients for tuberculosis before treatment. A switch should preserve the prescribed infliximab schedule while keeping the authorization and infusion logistics intact. Confirming the exact product and documenting continuity makes the administrative change easier to evaluate medically and financially.